LONG-TERM SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER AND BRCA MUTATIONS TREATED WITH OLAPARIB

Share

Share on facebook
Share on linkedin
Share on twitter
Share on email

In this double-blind phase III clinical trial, patients with newly diagnosed ovarian cancer and a BRCA mutation (germline or somatic) who responded to platinum-based chemotherapy were randomized to receive Olaparib or placebo for up to 2 years. After a 7-year follow-up, prespecified analysis of overall survival was reported.
This is the longest follow-up of a PARP inhibitor in the first-line setting that revealed clinically meaningful improvements in overall survival for patients treated with Olaparib.
At 7 years, 67.0% of Olaparib patients versus 46.5% of placebo patients were alive, and 45.3% versus 20.6%, respectively, were alive and had not received a first subsequent treatment (Kaplan-Meier estimates).
The results support the use of maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation to achieve long-term remission.

Download the new